Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...

It will detect the BCR-ABL1 gene for many months after you start treatment. So it can take a long time to have a deep molecular response. There are national guidelines for 'target' PCR results at ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in ...

the BCR-ABL gene You might see the BCR-ABL1 gene written in a more scientific way BCR::ABL1. Genetic tests are also done to look for other abnormal chromosomes . You might hear these tests called ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

In an ongoing phase 1 trial, 44% of 36 evaluable patients with previously treated CML have experienced a major molecular response—meaning the level of the BCR-ABL1 gene is reduced to 0.1% or ...

ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with ...

These data continued to compare favorably to precedent Phase 1 MMRs for approved BCR::ABL1 TKIs, particularly given the more heavily pre-treated patient population in the ELVN-001 clinical trial.

The team investigated when BCR::ABL1 first arises in a blood cell and how quickly these cells with this genetic change then multiply and expand to lead to a diagnosis of a type of leukemia.

Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia. Nature, 2025; DOI: 10.1038/s41586-025-08817-2 ...